RESUMO
Many neurodegenerative disorders share a common pathophysiological pathway involving axonal degeneration despite different etiological triggers. Analysis of cytoskeletal markers such as neurofilaments, protein tau and tubulin in cerebrospinal fluid (CSF) may be a useful approach to detect the process of axonal damage and its severity during disease course. In this article, we review the published literature regarding brain-specific CSF markers for cytoskeletal damage in primary progressive multiple sclerosis and amyotrophic lateral sclerosis in order to evaluate their utility as a biomarker for disease progression in conjunction with imaging and histological markers which might also be useful in other neurodegenerative diseases associated with affection of the upper motor neurons. A long-term benefit of such an approach could be facilitating early diagnostic and prognostic tools and assessment of treatment efficacy of disease modifying drugs.
Assuntos
Esclerose Lateral Amiotrófica/líquido cefalorraquidiano , Biomarcadores/líquido cefalorraquidiano , Lesões Encefálicas/genética , Esclerose Múltipla Crônica Progressiva/líquido cefalorraquidiano , Esclerose Lateral Amiotrófica/fisiopatologia , Encéfalo/patologia , Lesões Encefálicas/patologia , Citoesqueleto/patologia , Humanos , Neurônios Motores/metabolismo , Neurônios Motores/patologia , Esclerose Múltipla Crônica Progressiva/fisiopatologia , Tubulina (Proteína)/líquido cefalorraquidiano , Proteínas tau/líquido cefalorraquidianoRESUMO
The axonal cytoskeleton is a finely organized system, essential for maintaining the integrity of the axon. Axonal degeneration is implicated in the pathogenesis of unremitting disability of multiple sclerosis (MS). Purpose of this study is to evaluate levels of cytoskeletal proteins such as neurofilament light protein (NFL), glial fibrillary acidic protein (GFAP), and ß-tubulin (ß-Tub) isoforms II and III in the cerebrospinal fluid (CSF) of MS patients and their correlation with MS clinical indices. CSF levels of cytoskeletal proteins were determined in 51 patients: 33 with MS and 18 with other neurological diseases (OND). NFL, GFAP and ß-Tub II proteins were significantly higher (p < 0.0001) in MS than in OND group; no significant difference (p > 0.05) was found between MS and OND with regard to ß-Tub III. Interestingly, levels of ß-Tub III and NFL were higher in progressive than in remitting MS forms; on the contrary, higher levels of ß-Tub II and GFAP were found in remitting MS forms. However, with the exception of ß-Tub III, all proteins tend to decrease their CSF levels concomitantly with the increasing disability (EDSS) score. Overall, our results might indicate ß-Tub II as a potential candidate for diagnostic and ß-Tub III as a possible prognostic biomarker of MS. Therefore, further analyses are legitimated and desirable.
Assuntos
Proteína Glial Fibrilar Ácida/líquido cefalorraquidiano , Esclerose Múltipla/diagnóstico , Proteínas de Neurofilamentos/líquido cefalorraquidiano , Tubulina (Proteína)/líquido cefalorraquidiano , Adulto , Biomarcadores/líquido cefalorraquidiano , Progressão da Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla/líquido cefalorraquidiano , PrognósticoRESUMO
Neurocysticercosis (NC) presents two broad clinical entities: extraparenchymal (EP-NC) and parenchymal (P-NC). Using ELISA methodology, we demonstrate autoantibodies to tubulin and the Major oligodendrocyte glycoprotein (MOG) in the CSF of most, but not all, EP-NC samples. Levels of these autoantibodies were considerably reduced or absent in the P-NC samples. There was a striking correlation between levels of anti-tubulin and anti-MOG, and the significant correlation between the levels of autoantibodies and cellularity in the CSF, suggests that stimulation of the autoantibody response may be a function of cerebral inflammation. A hypothetical model to describe the pathogenesis of EP-NC is presented.
Assuntos
Autoanticorpos/líquido cefalorraquidiano , Encéfalo/diagnóstico por imagem , Glicoproteína Mielina-Oligodendrócito/líquido cefalorraquidiano , Neurocisticercose/líquido cefalorraquidiano , Neurocisticercose/diagnóstico por imagem , Tubulina (Proteína)/líquido cefalorraquidiano , Animais , Biomarcadores/líquido cefalorraquidiano , Equador/epidemiologia , Humanos , México/epidemiologia , Neurocisticercose/epidemiologia , Tecido Parenquimatoso/metabolismo , Fragmentos de Peptídeos/líquido cefalorraquidiano , SuínosRESUMO
HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is characterized by axonal degeneration of the corticospinal tracts. The specific requirements for transport of proteins and organelles to the distal part of the long axon are crucial in the corticospinal tracts. Microtubule dysfunction could be involved in this disease, configuring an axonal transport disease. We measured tubulin and its post-translational modified forms (acetylated and tyrosinated) in CSF of patients and controls, as well as tau and its phosphorylated forms. There were no significant differences in the contents of tubulin and acetyl-tubulin between patients and controls; tyrosyl-tubulin was not detected. In HAM/TSP, tau levels were significantly reduced, while the ratio of pT181/total tau was higher in patients than in controls, this being completely different from what is reported in other neurodegenerative diseases. Phosphorylation at T181 was also confirmed by Mass Spectrometry analysis. Western Blotting with monospecific polyclonal antibodies against pS199, pT205, pT231, pS262, pS356, pS396, pS404 and pS422 did not show differences in phosphorylation in these residues between patients and controls. Treating human SH-SY5Y neuroblastoma cells, a well-known in vitro neurite retraction model, with culture supernatant of MT-2 cells (HTLV-I infected cell line that secretes the viral Tax protein) we observed neurite retraction and an increase in tau phosphorylation at T181. A disruption of normal phosphorylation of tau protein in T181 could result in its dysfunction, contributing to axonal damage.
Assuntos
Vírus Linfotrópico T Tipo 1 Humano , Paraparesia Espástica Tropical/líquido cefalorraquidiano , Tubulina (Proteína)/líquido cefalorraquidiano , Proteínas tau/líquido cefalorraquidiano , Idoso , Estudos de Casos e Controles , Linhagem Celular Tumoral , Ensaio de Imunoadsorção Enzimática , Humanos , Immunoblotting , Espectrometria de Massas , Pessoa de Meia-Idade , Neuritos/patologia , Fosforilação/efeitos dos fármacos , Fosforilação/fisiologia , Valores de Referência , Fatores de TempoRESUMO
Biomarkers in body fluids could help to predict and monitor neurological decline in people with multiple sclerosis (MS). We discuss markers for axonal damage in body fluids in people with MS. The most promising axonal marker for discriminating patients with MS from those with other neurological diseases is the neurofilament light chain in CSF. Antibodies against the heavy-chain isoform are associated with disease progression. Other studies have shown altered CSF concentrations of tau proteins, actin, tubulin, and 14-3-3 protein. Interestingly, the concentration of 24S-hydroxycholesterol was decreased in serum of patients with MS. No clear changes have been shown for the markers apolipoprotein E and neurospecific enolase. We describe three types of markers for axonal damage: markers that reflect processes in the CNS, those that reflect extraneural processes, and those that reflect whole-body changes. These concepts may be helpful for biomarker research in various neurodegenerative diseases.
Assuntos
Ácido Aspártico/análogos & derivados , Axônios/patologia , Biomarcadores/sangue , Biomarcadores/líquido cefalorraquidiano , Esclerose Múltipla/sangue , Esclerose Múltipla/líquido cefalorraquidiano , Degeneração Neural , Proteínas 14-3-3/sangue , Proteínas 14-3-3/líquido cefalorraquidiano , Actinas/sangue , Actinas/líquido cefalorraquidiano , Precursor de Proteína beta-Amiloide/sangue , Precursor de Proteína beta-Amiloide/líquido cefalorraquidiano , Apolipoproteínas E/sangue , Apolipoproteínas E/líquido cefalorraquidiano , Ácido Aspártico/sangue , Ácido Aspártico/líquido cefalorraquidiano , Humanos , Hidroxicolesteróis/sangue , Hidroxicolesteróis/líquido cefalorraquidiano , Esclerose Múltipla/patologia , Fosfopiruvato Hidratase/sangue , Fosfopiruvato Hidratase/líquido cefalorraquidiano , Valor Preditivo dos Testes , Tubulina (Proteína)/sangue , Tubulina (Proteína)/líquido cefalorraquidiano , Proteínas tau/sangue , Proteínas tau/líquido cefalorraquidianoRESUMO
The pathologic basis of disease progression in multiple sclerosis (MS) is thought to involve axonal degeneration, which contributes to the accumulation of neurological disability. Recent reports suggest that intrathecal concentrations of the neurofilament protein in relapsing remitting MS correlate with disease activity and the degree of disability. We sought to investigate the intrathecal levels of other cytoskeletal components of axons, primarily actin, tubulin and the light subunit of neurofilament (NFL) in patients with progressive MS and relevant controls and correlate results with clinical parameters of disease severity. Cerebrospinal fluid (CSF) concentrations of actin, tubulin and NFL were significantly increased in MS patients when compared to corresponding levels in patients with other inflammatory or non-inflammatory neurological diseases. Moreover, the intrathecal release of actin and tubulin, and to a lesser extent NFL, was significantly more marked in patients with primary and secondary progressive MS when compared to patients with relapsing remitting disease and was correlated with clinical disability. Our findings suggest that progressive MS is associated with the heightened intrathecal release of axonal cytoskeletal proteins, and that CSF actin, tubulin and NFL are reliable markers of axonal damage.
Assuntos
Actinas/líquido cefalorraquidiano , Axônios/metabolismo , Esclerose Múltipla/líquido cefalorraquidiano , Proteínas de Neurofilamentos/líquido cefalorraquidiano , Tubulina (Proteína)/líquido cefalorraquidiano , Citoesqueleto/metabolismo , Avaliação da Deficiência , Progressão da Doença , Humanos , Valor Preditivo dos TestesRESUMO
HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is characterized by axonal degeneration of the corticospinal tracts. The specific requirements for transport of proteins and organelles to the distal part of the long axon are crucial in the corticospinal tracts. Microtubule dysfunction could beinvolved in this disease, configuring an axonal transport disease. We measured tubulin and its posttranslational modified forms (acetylated and tyrosinated) in CSF of patients and controls, as well as tau and its phosphorylated forms. There were no significant differences in the contents of tubulin and acetyl-tubulinbetween patients and controls; tyrosyl-tubulin was not detected. In HAM/TSP, tau levels were significantly reduced, while the ratio of pT181/total tau was higher in patients than in controls, this being completely different from what is reported in other neurodegenerative diseases. Phosphorylation at T181 was also confirmed by Mass Spectrometry analysis. Western Blotting with monospecific polyclonal antibodies against pS199, pT205, pT231, pS262, pS356, pS396, pS404 and pS422 did not show differences in phosphorylation in these residues between patients and controls. Treating human SH-SY5Y neuroblastoma cells, a well-known in vitro neurite retraction model, with culture supernatant of MT-2 cells (HTLV-I infected cell line that secretes theviral Tax protein) we observed neurite retraction and an increase in tau phosphorylation at T181. A disruptionof normal phosphorylation of tau protein in T181 could result in its dysfunction, contributing to axonal damage.